Download PDF
Kinder- und Jugendmedizin 2016; 16(02): 108-116
DOI: 10.1055/s-0037-1616310
Dermatologie
Schattauer GmbH

Infantile Hämangiome

Ein UpdateInfatile hemangiomasAn update
M. Pleimes
1   Praxis für Kinder- und Jugendhaut, Heidelberg
› Author Affiliations
Further Information

Publication History

Eingereicht am: 31 December 2015

angenommen am: 07 January 2016

Publication Date:
11 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Infantile Hämangiome sind mit einer Prävalenz von 2,6–4,5 % die häufigsten Tumoren des Säuglings- und Kleinkindesalters. Im Gegensatz zu vielen anderen Tumoren haben sie nach einer anfänglichen Proliferationsphase die Eigenschaft einer spontanen Remission durch Involution. Ein Großteil der Hämangiome kann diese Abfolge spontan durchlaufen, ohne dass therapeutisch interveniert werden muss. Bei einem kleinen Teil der Hämangiome kommt es jedoch schon frühzeitig zu Komplikationen, welche selten lebensbedrohlich sein können, aber oft bleibende funktionelle Schäden, Schmerzen oder dauerhaft entstellende Befunde hinterlassen. Die Herausforderung für den niedergelassenen Pädiater ist es, diese Fälle frühzeitig zu erkennen und einer entsprechenden Therapie zuzuführen. Dabei stehen je nach Lage und Art des Hämangioms sowie der Größe, welche auch vom Zeitpunkt der Erstpräsentation abhängt, unterschiedliche therapeutische Optionen zur Verfügung. Gerade in der sehr frühen Phase lassen sich manchmal sowohl Folgeschäden als auch Therapieintensität und -dauer positiv beeinflussen.

In diesem Artikel sollen Eigenschaften infantiler Hämangiome, Entwicklungsverlauf und therapeutische Modalitäten daher aktualisiert besprochen werden.

Summary

Infantile hemangiomas, with a prevalence of 2.6 to 4.5 %, are the most common benign tumors of infancy. Following an initial period of proliferation they have the capability of spontaneous remission by involution. The majority of infantile hemangiomas will pass through this sequence without need of intervention. In a small percentage of infantile hemangiomas, however, complications can occur, which rarely may be life threatening, but often leave permanent functional damage, pain or disfigurement. The challenge for the pediatrician is to identify these cases at an early stage and to initiate adequate therapy. Depending on the localization, subtype and size of infantile hemangioma, where size varies with the time of first presentation, different therapeutic options are available. Especially in the very early stages possible distortion, tissue damage as well as treatment intensity and duration can be influenced positively. This article will summarize and update the current knowledge on properties, development, diagnostics and therapy of infantile hemangiomas.

Schlüsselwörter

Infantiles Hämangiom - vaskulärer Tumor - vaskuläre Anomalien

Keywords

Infantile hemangioma - vascular tumor - vascular anomalies
 

  • Literatur

  • 1 Wassef M, Blei F, Adams D. et al. Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136: e203-214.
    CrossrefGoogle Scholar
  • 2 Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 2004; 50: 875-882.
    CrossrefPubMedGoogle Scholar
  • 3 North PE, Waner M, Mizeracki A, Mihm MC. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000; 31: 11-22.
    CrossrefGoogle Scholar
  • 4 North PE, Waner M, James CA. et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch Dermatol 2001; 137: 1607-1620.
    Google Scholar
  • 5 Darrow DH, Greene AK, Mancini AJ. et al. Diagnosis and Management of Infantile Hemangioma. Pediatrics 2015; 136: e1060-1104.
    CrossrefGoogle Scholar
  • 6 Hoeger PH, Harper JI, Baselga E. et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015; 174: 855-865.
    CrossrefGoogle Scholar
  • 7 Schmittenbecher PP, Grantzow R, Rößler JH. et al. S2k Leitlinie der DGKCh, DGKJ, DDG, DGMKG: Infantile Hämangiome im Säuglings- und Kleinkindesalter. AWMF Leitlinien. 2015; AWMF Register Nr. 006/100: 1-13.
    Google Scholar
  • 8 Theiler M, Walchli R, Weibel L. Vascular anomalies – a practical approach. J Dtsch Dermatol Ges 2013; 11: 397-405.
    Google Scholar
  • 9 Dickison P, Christou E, Wargon O. A prospective study of infantile hemangiomas with a focus on incidence and risk factors. Pediatr Dermatol 2011; 28: 663-669.
    CrossrefGoogle Scholar
  • 10 Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25: 168-173.
    CrossrefPubMedGoogle Scholar
  • 11 Munden A, Butschek R, Tom WL. et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 2014; 170: 907-913.
    CrossrefGoogle Scholar
  • 12 Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed 2015; 100: F85-91.
    CrossrefGoogle Scholar
  • 13 Janmohamed SR, Madern GC, de Laat PC, Oranje AP. Educational paper: Pathogenesis of infantile haemangioma, an update 2014 (part I). Eur J Pediatr 2015; 174: 97-103.
    CrossrefGoogle Scholar
  • 14 Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents’ photographs tell us. Pediatrics 2012; 130: e314-320.
    CrossrefGoogle Scholar
  • 15 Chang LC, Haggstrom AN, Drolet BA. et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122: 360-367.
    CrossrefGoogle Scholar
  • 16 Haggstrom AN, Drolet BA, Baselga E. et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118: 882-887.
    CrossrefGoogle Scholar
  • 17 Mulliken JB, Burrows PE, Fishman SJ, Mulliken JB. Mulliken and Young’s vascular anomalies: hemangiomas and malformations. Oxford: Oxford University Press; 2013: xviii 1118.
    Google Scholar
  • 18 Dickie B, Dasgupta R, Nair R. et al. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg 2009; 44: 125-133.
    CrossrefPubMedGoogle Scholar
  • 19 Shin HT, Orlow SJ, Chang MW. Ulcerated haemangioma of infancy: a retrospective review of 47 patients [letter]. Br J Dermatol 2007; 156: 1050-1052.
    CrossrefGoogle Scholar
  • 20 Bauland CG, Luning TH, Smit JM. et al. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg 2011; 127: 1643-1648.
    CrossrefGoogle Scholar
  • 21 Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution. J Pediatr 1997; 131: 643-646.
    CrossrefGoogle Scholar
  • 22 An update on infantile haemangiomas. [editorial]. Br J Dermatol 2013; 169: 11.
    Google Scholar
  • 23 Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735-746.
    CrossrefGoogle Scholar
  • 24 Léauté-Labrèze C, Dumas de la Roque E, Hubiche T. et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008; 358: 2649-2651.
    CrossrefGoogle Scholar
  • 25 Dermo-Kosmetiks PF. Fachinfo: HEMANGIOL® 3,75 mg/ml Lösung zum Einnehmen. Rote Liste Fachinfo Service; 20141-20146.
    Google Scholar
  • 26 Drolet BA, Frommelt PC, Chamlin SL. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131: 128-140.
    CrossrefPubMedGoogle Scholar
  • 27 Bernabeu-Wittel J, Narváez-Moreno B, de la Torre-García JM. et al. Oral Nadolol for Children with Infantile Hemangiomas and Sleep Disturbances with Oral Propranolol. Pediatr Dermatol 2015; 32: 853-857.
    CrossrefGoogle Scholar
  • 28 Pope E, Chakkittakandiyil A, Lara-Corrales I. et al. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol 2013; 168: 222-224.
    CrossrefGoogle Scholar
  • 29 Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics 2013; 131: e1739-1747.
    CrossrefGoogle Scholar
  • 30 Ovadia SA, Landy DC, Cohen ER. et al. Local administration of -blockers for infantile hemangiomas: a systematic review and meta-analysis. Ann Plast Surg 2015; 74: 256-262.
    CrossrefGoogle Scholar
  • 31 Qiu Y, Yang J, Chen M. et al. A prospective self-controlled study of topical timolol 0.5 % cream for large superficial infantile hemangiomas. J Dermatol 2015; 42: 363-366.
    CrossrefGoogle Scholar
  • 32 Schneider M, Reimer A, Cremer H, Ruef P. Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas. World J Pediatr 2014; 10: 313-317.
    CrossrefGoogle Scholar
  • 33 Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution. J Pediatr 1996; 128: 329-335.
    CrossrefGoogle Scholar
  • 34 Enjolras O, Picard A, Soupre V. [Congenital haemangiomas and other rare infantile vascular tumours]. Ann Chir Plast Esthet 2006; 51: 339-346.
    CrossrefGoogle Scholar
  • 35 Frieden IJ, Reese V, Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996; 132: 307-311.
    CrossrefGoogle Scholar
  • 36 Girard C, Bigorre M, Guillot B, Bessis D. PELVIS Syndrome. Arch Dermatol 2006; 142: 884-888.
    Google Scholar
  • 37 Iacobas I, Burrows PE, Frieden IJ. et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr 2010; 157: 795-801.e1.
    CrossrefGoogle Scholar
  • 38 Metry DW, Haggstrom AN, Drolet BA. et al. A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. Am J Med Genet A 2006; 140: 975-986.
    Google Scholar
  • 39 Metry DW, Siegel DH, Cordisco MR. et al. A comparison of disease severity among affected male versus female patients with PHACE syndrome. J Am Acad Dermatol 2008; 58: 81-87.
    CrossrefGoogle Scholar
  • 40 Stockman A, Boralevi F, Taieb A, Leaute-Labreze C. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology 2007; 214: 40-45.
    CrossrefGoogle Scholar